BOSTON, MA -- (MARKET WIRE) -- January 03, 2007 -- Despite a growing list of development challenges -- including rising R&D costs, increasing regulatory stringency, and mounting public hostility over safety and end-user costs -- drug developers have cause for optimism, according to the Tufts Center for the Study of Drug Development.
